<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02038036</url>
  </required_header>
  <id_info>
    <org_study_id>CINC424B2401</org_study_id>
    <nct_id>NCT02038036</nct_id>
  </id_info>
  <brief_title>Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.</brief_title>
  <acronym>RESPONSE-2</acronym>
  <official_title>Randomized, Open Label, Multicenter Phase IIIb Study Evaluating the Efficacy and Safety of Ruxolitinib Versus Best Available Therapy in Patients With Polycythemia Vera Who Are Hydroxyurea Resistant or Intolerant (Response 2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will compare the efficacy and safety of ruxolitinib to Best Available Therapy
      (BAT) in patients with polycythemia vera (PV) who are hyroxyurea (HU) resistant or intolerant
      and do not have a palpable spleen.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 25, 2014</start_date>
  <completion_date type="Anticipated">April 20, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 20, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of ruxolitinib to Best Available Therapy (BAT) as assessed by Hct control at Week 28</measure>
    <time_frame>Week 28</time_frame>
    <description>Proportion of patients achieving Hct control at Week 28 as defined by: •Hct &lt; 45% at Week 16 and maintained until Week 28, and •No phlebotomy from Week 4 to Week 28, with no more than one phlebotomy occurring post randomization and prior to the Week 4 visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of ruxolitinib to BAT as assessed by peripheral blood count remission at Week 28.</measure>
    <time_frame>Week 28</time_frame>
    <description>Proportion of patients achieving a peripheral blood count remission at Week 28 as defined by: Hct &lt; 45% at Week 16 and maintained until Week 28, and WBC &lt; 10 x10E9/L at Week 16 and maintained until Week 28, and Platelets ≤ 400 x 10E9/L at Week 16 and maintained until Week 28, and No phlebotomy from Week 4 to Week 28, with no more than one phlebotomy occurring post randomization and prior to the Week 4 visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of ruxolitinib to BAT as assessed by durable Hct control at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>Proportion of patients achieving a Hct control at Week 52 as defined by: Hct &lt; 45% at Week 16 and maintained until Week 52, and no phlebotomy from Week 4 to Week 28, with no more than one phlebotomy occurring post randomization and prior to the Week 4 visit, and, in the BAT arm, no change in the treatment regimen or crossover to the ruxolitinib arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of ruxolitinib to BAT as assessed by durable peripheral blood count remission at Week 52.</measure>
    <time_frame>Week 52</time_frame>
    <description>Proportion of patients achieving a peripheral blood count remission at Week 52 as defined by: •Hct &lt; 45% at Week 16 and maintained until Week 52, and WBC &lt; 10 x10E9/L at Week 16 and maintained until Week 52, and Platelets ≤ 400 x 10E9/L at Week 16 and maintained until Week 52, and, no phlebotomy from Week 4 to Week 52, with no more than one phlebotomy occurring post randomization and prior to the Week 4 visit, and in the BAT arm, no change in the treatment regimen or crossover to the ruxolitinib arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ECOG status</measure>
    <time_frame>Week 28</time_frame>
    <description>Change in ECOG status from baseline to Week 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in spleen length</measure>
    <time_frame>Week 4, 8, 12, 16, 20, 24, 28, 40, 52/End of Treatment</time_frame>
    <description>Change from Baseline in spleen length at each scheduled visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of ruxolitinib to BAT as assessed by partial remission based on the ELN and IWG-MRT criteria at Week 28</measure>
    <time_frame>Week 28</time_frame>
    <description>Proportion of patients achieving a partial remission at Week 28, based on the ELN and IWG-MRT criteria, as defined by: •MPN-SAF TSS score reduction of greater than or equal to 10 points from baseline to Week 16 and maintained until Week 28 (for patients with a baseline score of 20 or more), and •Hct &lt; 45% at Week 16 and maintained until Week 28, and •No phlebotomy from Week 4 to Week 28, with no more than one phlebotomy occurring post randomization and prior to the Week 4 visit, and •WBC &lt; 10 x10E9/L at Week 16 and maintained until Week 28, and •Platelets ≤ 400 x 10E9/L at Week 16 and maintained until Week 28, and •No palpable spleen at Week 16 and maintained until Week 28, and •No hemorrhagic or thrombotic events, and •No transformation into post-PV myelofibrosis, myelodysplastic syndrome, or acute leukemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of ruxolitinib to BAT as assessed by durable partial remission based on the ELN and IWG-MRT criteria at Week 52.</measure>
    <time_frame>Week 52</time_frame>
    <description>Proportion of patients who achieved partial remission at Week 52, based on the ELN and IWG-MRT criteria, as defined by: •MPN-SAF TSS score reduction of greater than or equal to 10 points from baseline to Week 16 and maintained until Week 52 (for patients with a baseline score of 20 or more), and •Hct &lt; 45% at Week 16 and maintained until Week 52, and •No phlebotomy from Week 4 to Week 52, with no more than one phlebotomy occurring post randomization and prior to the Week 4 visit, and •WBC &lt; 10 x10E9/L at Week 16 and maintained until Week 52, and •Platelets ≤ 400 x 10E9/L at Week 16 and maintained until Week 52, and •No palpable spleen at Week 16 and maintained until Week 52, and •No hemorrhagic or thrombotic events, and •No transformation into post-PV myelofibrosis, myelodysplastic syndrome (IWG-MRT criteria) or acute leukemia (WHO criteria), and •In the BAT arm, no change in the treatment regimen or crossover to the ruxolitinib arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of BAT patients after they cross over to ruxolitinib</measure>
    <time_frame>+4, +8, +12, +16, +20, +24 weeks after crossover</time_frame>
    <description>Among patients randomized to BAT who cross over to ruxolitinib, proportion of patients achieving Hct &lt; 45% at each visit after cross over</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in MPN-SAF TSS</measure>
    <time_frame>Week 4, 8, 16, 28, 40, 52/End of Treatment</time_frame>
    <description>Proportion of patients achieving at least a 50% reduction from baseline in MPN-SAF TSS score at each visit where it is measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resolution of disease related symptoms in MPN-SAF TSS at Week 28.</measure>
    <time_frame>Week 28</time_frame>
    <description>Proportion of patients achieving a resolution of disease related symptoms in MPN-SAF TSS at Week 28 defined as: • MPN-SAF TSS score reduction of greater than or equal to 10 points from baseline to Week 16 and maintained until Week 28 (for patients with a baseline score of 20 or more).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in patient reported outcomes</measure>
    <time_frame>Week 4, 8, 16, 28, 40, 52/End of Treatment</time_frame>
    <description>Change in MPN-SAF TSS from baseline to each visit where measured.
PSIS at each visit where measured.
Change in EQ-5D-5L score from baseline to each visit where measured.
Change in WPAI from baseline to each visit where measured.
PGIC at each visit where measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of ruxolitinib and Best Available Therapy</measure>
    <time_frame>Week 28, 52/EoT</time_frame>
    <description>Safety will be assessed by monitoring the frequency, duration and severity of Adverse Events, and evaluating changes in vital signs, electrocardiograms (ECGs), serum chemistry, hematology and urinalysis results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of BAT patients after they crossover</measure>
    <time_frame>+52/EoT</time_frame>
    <description>Safety will be assessed by monitoring the frequency, duration and severity of Adverse Events, and evaluating changes in vital signs, electrocardiograms (ECGs), serum chemistry, hematology and urinalysis results.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">149</enrollment>
  <condition>Polycythemia Vera</condition>
  <arm_group>
    <arm_group_label>Ruxolitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>52 patients- at a starting dose of 10 mg bid. Dose may be adjusted based on efficacy and safety parameters up to a maximum dose of 25 mg bid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Best Available Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>52 patients - as selected by the investigator from: Hydroxyurea, IFN/PEG-IFN, popobroman, anagrelide, IMIDs, or observation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Best Available Therapy</intervention_name>
    <description>Best Available Therapy as selected by the investigator from the below: 1. Hydroxyurea 2. IFN/PEG-IFN 3. Pipobroman 4. Anagrelide 5. IMIDs 6. Observation only</description>
    <arm_group_label>Best Available Therapy</arm_group_label>
    <other_name>BAT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ruxolitinib</intervention_name>
    <description>Supplied as tablets. Starting dose of 10 mg bid. Based on efficacy and safety parameters, dose may be increased or decreased. Maximum dose allowed is 25mg bid.</description>
    <arm_group_label>Ruxolitinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of PV according to the 2008 World Health Organization criteria,
             Non-palpable spleen, Phlebotomy dependent, Resistant to or intolerant of hydroxyurea,
             ECOG performance status of 0, 1 or 2.

        Exclusion Criteria:

          -  Inadequate liver or renal function, Significant bacterial, fungal, parasitic, or viral
             infection requiring treatment, Active malignancy within the past 5 years, excluding
             specific skin cancers, Previously received treatment with a JAK inhibitor, Being
             treated with any investigational agent, Women who are pregnant or nursing. Other
             inclusion/exclusion criteria apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Antwerpen</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bayonne</city>
        <state>Bayonne cedex</state>
        <zip>64109</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lille cedex</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nice Cedex</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Strasbourg cedex</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Württemberg</state>
        <zip>68305</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Augsburg</city>
        <zip>86150</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jena</city>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Minden</city>
        <zip>32429</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>H-1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaposvar</city>
        <zip>7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500 096</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vellore</city>
        <state>Tamil Nadu</state>
        <zip>632 004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700 054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nahariya</city>
        <zip>22100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Netanya</city>
        <zip>42150</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Firenze</city>
        <state>FI</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pavia</city>
        <state>PV</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Varese</city>
        <state>VA</state>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Malaga</city>
        <state>Andalucia</state>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salamanca</city>
        <state>Castilla y Leon</state>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alicante</city>
        <state>Comunidad Valenciana</state>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>La Coruna</city>
        <state>Galicia</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <state>Las Palmas de G.C</state>
        <zip>35010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Izmir</city>
        <zip>35040</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Talas / Kayseri</city>
        <zip>38039</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>Turkey</country>
  </location_countries>
  <removed_countries>
    <country>Switzerland</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2014</study_first_submitted>
  <study_first_submitted_qc>January 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2014</study_first_posted>
  <last_update_submitted>October 3, 2017</last_update_submitted>
  <last_update_submitted_qc>October 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Polycythemia Vera</keyword>
  <keyword>Hematologic Diseases</keyword>
  <keyword>Myeloproliferative Disorders</keyword>
  <keyword>Bone Marrow Diseases</keyword>
  <keyword>Hydroxyurea</keyword>
  <keyword>INC424</keyword>
  <keyword>Ruxolitinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Polycythemia Vera</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxyurea</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

